http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

A lot of excitement across the boards today about this share.

No stopping this one.

Summit Corporation PLC (SUMM:LSE) set a new 52-week high during today's trading session when it reached 19.18. Over this period, the share price is up 424.14%.

Yep, indeed!...going skyhigh....just like PLE....then hopefully LBB, MDZ, PIRI, COMS, CEE, QPP amongst others (already done well with REM having bought b4 the surge and have taken profits since)

sorry, that's CCE, not CEE!

22 Aug N+1 Singer 10.70 Buy - Looking dated now the sp is at 19p . As Delia Smith would say to N+1 Singer '' Lets be aving yer''. lol

APPOINTMENT OF NOMINATED ADVISER

Oxford, UK, 26 September 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, is pleased to announce the appointment with immediate effect of Cairn Financial Advisers as the Company's Nominated Adviser (Nomad).

- END -

Summit to present at California medical congress
By John Harrington September 30 2013, 2:05pm Summit is an Oxford based drug discovery and development company targeting high-value areas of unmet medical need including DMD and C. difficile infection.Summit is an Oxford based drug discovery and development company targeting high-value areas of unmet medical need including DMD and C. difficile infection.

Summit (LON:SUMM) is to give a presentation on one of its lead drugs at the 18th International World Muscle Society congress in California.

The poster presentation, entitled "Future clinical and biomarker development for SMT C1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy", will outline the proposed clinical development plan to achieve proof of concept for SMT C1100 in Duchenne muscular dystrophy (DMD) patients.

Summit's C1100 development drug has the potential to maintain healthy muscle tone. This offers a potential breakthrough in treating DMD, a rare wasting disease that affects boys only (and 1,500 here in the UK).

Details will also be presented on the supporting biomarker programme that aims to develop new exploratory clinical endpoints to help evaluate the benefit of therapies such as SMT C1100 in future DMD patient trials.

The Congress is taking place from 1 October to 5 October.

A copy

A link to the above :- Summit to Present Clinical and Biomarker Programmes for DMD at WMS

A copy of the presentation put on the company website today -

http://www.summitplc.com/userfiles/file/WMS%202013%20FINAL(1).pdf

sp down 10% @13p profit taking?

A good 8% pull back today.

And another 10%

Summit Receives Regulatory Approval to Start Ph...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT RECEIVES REGULATORY APPROVAL TO START PHASE 1B CLINICAL TRIAL OF SMT C1100 IN DMD PATIENTS

Oxford, UK, 1 November 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, announces that its Phase 1b Clinical Trial Application for SMT C1100 has received approval from the UK Medicines and Healthcare products Regulatory Agency ('MHRA') and the Ethics Review Committee. SMT C1100 is a small molecule utrophin modulator that has the potential to treat all patients with DMD, regardless of the underlying genetic fault.

"Securing regulatory approval for the first in patient Phase 1b clinical trial has achieved another important milestone in the development of utrophin modulator, SMT C1100, for DMD," commented Glyn Edwards, Chief Executive Officer. "We believe that utrophin modulation is a novel disease-modifying approach for all boys with DMD and this Phase 1b trial forms an integral part of our wider clinical plans towards establishing SMT C1100 as a viable treatment for this devastating condition."

The Phase 1b trial will be a dose-escalating, open-label study and will be conducted in a total of 12 paediatric patients with DMD, aged between 5 and 11 years. It will evaluate the safety and tolerability of SMT C1100, and will measure blood concentration levels of the drug as Summit aims to confirm the dose to be used in a subsequent patient proof of concept efficacy trial. The Phase 1b trial will be conducted at up to four NHS hospitals located in the UK and patient recruitment is expected to start shortly.

The Chief Investigator for the trial, Professor Francesco Muntoni, Paediatric Neurologist at Great Ormond Street Hospital and Director of the Dubowitz Neuromuscular Centreadded, "Utrophin is a promising approach for the treatment of all DMD patients, regardless of their genetic mutation. It also has the potential to be complementary to other therapeutics approaches in clinical development and the start of the first patient trial of SMT C1100 is an important moment for the whole DMD community."

Further details about the clinical trial will be made available via www.clinicaltrials.gov and www.clinicaltrialsregister.eu.

- END -

Sounds promising!

1 Nov N+1 Singer 11.00 Buy

Shares in drug developer Summit Corporation (LON:SUMM) may not have got the shot in the arm it was hoping for, but twice the normal number of shares traded changed hands on the day.

Summit received UK regulatory approval to start patient trials of its SMT C1100 drug.

SMT C1100 is being developed for use in the treatment of the fatal muscle wasting disease Duchenne Muscular Dystrophy (DMD). It has the potential to treat all patients with DMD, regardless of the underlying genetic fault.

The Phase 1b trial will be a dose-escalating, open-label study and will be conducted in a total of 12 paediatric patients with DMD, aged between 5 and 11 years.

The study will evaluate the safety and tolerability of SMT C1100, and will measure blood concentration levels of the drug as Summit aims to confirm the dose to be used in a subsequent patient proof of concept efficacy trial.



http://www.proactiveinvestors.co.uk/companies/market_reports/62824/proactive-news-summary-falcon-oil-gas-summit-corporation-metminco-fastjet-rurelec-0000.html

Summit and Joining Jack Enter Funding Agreement...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT AND JOINING JACK ENTER FUNDING AGREEMENT TO SUPPORT DEVELOPMENT OF NOVEL BIOMARKERS FOR DMD

Oxford, UK, 5 November 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, is pleased to announce it has entered into a funding agreement with the UK charity, Joining Jack, to support the development of novel biomarkers for DMD.

Summit aims to develop new biomarkers that are both related to the mechanism of its utrophin modulator candidate SMT C1100 and to other aspects of muscle health, including muscle fibre regeneration and inflammation. The information gained from this effort will support the clinical development of SMT C1100 and other therapeutic candidates for the treatment of DMD. Joining Jack were formed in 2012 to support research into identifying therapies for DMD and they will provide up to £100,000 in funding to support this development effort.

"Summit is delighted to enter this agreement with Joining Jack to support our development programme to create novel and meaningful biomarkers to help determine the impact of new candidates like SMT C1100 in clinical trials and to supplement the existing endpoints, which are often seen as limited and challenging," commented Glyn Edwards, Chief Executive Officer of Summit. "We are grateful for the continuing support of the DMD community in advancing this therapeutic approach which could potentially treat all patients with DMD, regardless of the underlying genetic cause."

Andrew Johnson from Joining Jack added: "Our mission is to provide support for potential new therapies in DMD to ultimately ensure that we can make a difference for this generation of boys suffering from this disease. We believe that SMT C1100 and the utrophin modulation approach holds significant promise."

The biomarker development work will be conducted in collaboration with the leading research groups of Dr Jenny Morgan, Professor Caroline Sewry and Professor Francesco Muntoni at the Institute of Child Health, University College London.

- END -

N+1 Singer Buy 10.13 10.13 11.00 16.30 Reiterates

Summit and the University of Oxford Enter Strategic Alliance to Develop Treatments for DMD

SUMMIT AND THE UNIVERSITY OF OXFORD ENTER STRATEGIC ALLIANCE TO DEVELOP TREATMENTS FOR DUCHENNE MUSCULAR DYSTROPHY


Summit acquires exclusive rights to a pipeline of novel utrophin modulators and core technology, and an exclusive option to intellectual property arising from the research collaboration

Technology acquired through issue of up to 42.5 million new ordinary shares